Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Pelthos Therapeutics received a “Moderate Buy” consensus rating from six analysts, with five issuing buy ratings and one recommending hold. The average 12-month price target is $55.40, although Oppenheimer recently lowered its target to $64 from $66 while maintaining an outperform rating.
• The company reported a quarterly loss of $6.62 per share on $15.60 million in revenue, alongside a negative net margin of 165.24% and negative return on equity of 204.71%. Analysts expect a full-year loss of $15.22 per share.
• PTHS opened at $23.24 and has traded between $18.19 and $37.50 over the past year. Institutional investors own nearly 78% of the stock, while hedge fund Knott David M. Jr. increased its position by 9.3% during the first quarter.

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $55.40.

Separately, Oppenheimer decreased their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an "outperform" rating for the company in a report on Friday, August 14th.

Pelthos Therapeutics Trading Up 0.4%

PTHS opened at $23.24 on Wednesday. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. Pelthos Therapeutics has a fifty-two week low of $18.19 and a fifty-two week high of $37.50. The company's 50 day moving average price is $25.75 and its two-hundred day moving average price is $25.35. The firm has a market capitalization of $89.01 million, a price-to-earnings ratio of -1.06 and a beta of 3.01.

Pelthos Therapeutics (NYSEAMERICAN:PTHS - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The company had revenue of $15.60 million for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. As a group, research analysts predict that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its position in Pelthos Therapeutics stock. Knott David M Jr raised its holdings in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Free Report) by 9.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,073 shares of the company's stock after buying an additional 1,792 shares during the quarter. Knott David M Jr owned 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent SEC filing. Institutional investors own 77.96% of the company's stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.